Quick Takeaways:
- VolitionRx announced submission of a clinical manuscript for peer review, highlighting the performance of its Nu.Q Vet Feline prototype assay for detecting feline lymphoma, the most common cancer in cats. The blood-based liquid biopsy assay achieved 86% sensitivity at 97% specificity, positioning it as a potential first-in-class, affordable feline cancer screening test.
- The study demonstrated that circulating H3.1-nucleosome levels were significantly elevated in cats with intermediate-large cell lymphoma compared to healthy controls, supporting nucleosomes as a promising biomarker for feline cancer screening.
- Volition stated that publication of the peer-reviewed study is expected to trigger a $5M contractual milestone payment and support commercialization of the test through reference laboratories and point-of-care platforms. With the Nu.Q Vet Canine test already available in over 20 countries, the company believes a feline equivalent could potentially double its addressable companion animal market.
Why It Matters?
Volition is positioning Nu.Q Vet Feline as a potential first scalable, affordable blood test for feline lymphoma, with performance (86% sensitivity at 97% specificity) strong enough to support real-world screening, not just “rule‑in” use.
If the manuscript is accepted and the 5 million dollar milestone triggers, Volition gets both non‑dilutive funding and scientific validation, de‑risking commercialization via reference labs and point‑of‑care platforms and effectively doubling its companion‑animal opportunity by adding cats to a Nu.Q Vet canine footprint that already spans 20‑plus countries.
Source: PRnewswire
